Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Análogos no glucosídicos de a-GalCer como activadores de células NKT

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20180116002
Publicado:
05/04/2018
Caducidad:
06/04/2019
Resumen:
Un centro de investigación español ha desarrollado nuevos análogos no glucosídicos de alfa-galactosilceramida (a-GalCer) que inducen la proliferación de células NKT implicadas en respuestas inmunes. Estos compuestos son moduladores versátiles de la producción de citoquina y tienen potencial como medicamentos en terapia o como adyuvantes para vacunas en inmunoterapias del cáncer, infecciones o enfermedades autoinmunes. Los derivados no glucosídicos han mostrado una fuerte actividad in vitro para estimular células iNKT induciendo la liberación de citoquinas. El centro de investigación, con amplia experiencia en desarrollar nuevos compuestos bioactivos y probarlos como candidatos potenciales para el tratamiento de enfermedades basados en la activación de la respuesta inmune, busca socios industriales con el fin de licenciar la patente.

Details

Tittle:
Non-glycosidic analogues of a-GalCer as NKT cell activators
Summary:
A Spanish research institution has developed novel non-glycosidic analogues of alpha-galactosylceramide (a-GalCer) that induce proliferation of natural killer T (NKT) cells, involved in immune responses. These compounds are versatile modulators of cytokine production.They have potential as drugs in therapy or as adjuvants for vaccines in cancer immunotherapies, infections or autoimmune diseases. Industrial partners are being sought to collaborate through a patent licence agreement.
Description:
Invariant natural killer T cells (iNKT), a unique subpopulation of T cells with immunomodulatory properties involved in a broad range of immune responses, are stimulated by glycolipid antigens, particularly by alpha-galactosylceramide (a-GalCer).
Due to the exceptional potency of a-GalCer on iNKT cell stimulation that simultaneously induces the expression of Th1 and Th2 cytokines, with opposite functions and the subsequent side effects, new compounds are needed to achieve selective modulation of cytokine release.
A new family of non-glycosidic analogues of a-GalCer has been developed. These non-glycosidic derivatives have shown a strong activity in vitro to stimulate iNKT cells by inducing cytokine release. The compounds have shown activity in human iNKT cell stimulation.
Due to the role of iNKT cells, these compounds can have application in cancer immunotherapy for cooperative stimulation of the patient immune system and as vaccine adjuvants in autoimmune diseases or infections.
The Spanish research group has a broad experience in developing novel bio active compounds to be tested as potential candidates for treatment of diseases based on the activation of the inmune response.
The Spanish research centre is searching for a company interested in the development and commercialization of these novel compounds under a license agreement. The compounds have only been tested at a laboratory scale, therefore some further development might be needed and the Spanish research centre could collaborate with the company in that project.
Advantages and Innovations:
· Replacement of the galactose moiety by a non-glycosidic group avoids degradation by cellular glycosidases, conferring a longer half life and therefore sustained effects.
· These analogues can modulate Th1/Th2 induced cytokine production, promoting selectively Th2 or Th1 synthesis depending on the chemical diversity introduced.
· Defined mechanism of action, involving CD1d presentation by antigen presenting cells and stimulation of NKT cell proliferation.
· NKT cells are unconventional regulators of innate and adaptive immunity. Activation of iNKT initiates an adjuvant cascade that reinforces the innate immunity and promotes the subsequent adaptive immune response.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Priority patent application filed suitable for international extension

Partner sought

Type and Role of Partner Sought:
- Type of partner sought: Pharmaceutical company
- Specific area of activity of the partner: immunology, vaccine producers, cancer
- Task to be performed by the partner sought:preclinical and clinical trials

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001006 Vacunas humanas